Mabwell to Showcase Cervical Cancer Drug Data at ESMO GC 2026
Event summary
- Mabwell will present updated Phase I/II data on 9MW2821 for cervical cancer in an oral session at ESMO GC 2026 on June 17.
- Preliminary Phase Ib/II combination data with Toripalimab will be featured in a poster presentation on June 18.
- Presentations led by key oncologists from Fudan University and Zhejiang Cancer Hospital.
- 9MW2821 is a novel Nectin-4 targeting ADC (antibody-drug conjugate) for recurrent/metastatic cervical cancer.
The big picture
Mabwell's presentations at ESMO GC 2026 come as ADC therapies gain momentum in oncology, particularly for hard-to-treat cancers like cervical cancer. The focus on combination strategies reflects broader industry trends toward multi-modal treatments. Success here could position 9MW2821 as a competitive option in a market increasingly dominated by established players like Seagen and Roche.
What we're watching
- Clinical Efficacy
- How the updated Phase I/II data will position 9MW2821 against existing cervical cancer treatments.
- Combination Strategy
- Whether the Toripalimab combination shows sufficient synergistic potential to warrant further development.
- Regulatory Pathway
- The pace at which Mabwell can advance 9MW2821 toward potential regulatory filings based on these results.